美国基因治疗公司MeiraGTx宣布,与礼来达成一项潜在总值超过4.75亿美元的授权协议,礼来将获得用于治疗罕见遗传性失明疾病的实验性基因疗法权利。根据协议,MeiraGTx将获得7500万美元的预付款,并有机会再获逾4亿美元的里程碑付款。此外,公司还有资格就授权产品收取分级权利金。
美国基因治疗公司MeiraGTx宣布,与礼来达成一项潜在总值超过4.75亿美元的授权协议,礼来将获得用于治疗罕见遗传性失明疾病的实验性基因疗法权利。根据协议,MeiraGTx将获得7500万美元的预付款,并有机会再获逾4亿美元的里程碑付款。此外,公司还有资格就授权产品收取分级权利金。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.